Christopher Michael Pleiman
Hearing Aid Provider in Salt Lake City, UT
License number
Utah 5197321-8914
Issued Date
Nov 5, 2002
Expiration Date
May 31, 2011
Category
xControlled Substance Handler
Type
Controlled Substance Handler Individual
Address
Address
Salt Lake City, UT
Personal information
See more information about Christopher Michael Pleiman at radaris.comName
Address
Phone
1931 Southmoor Dr, Salt Lake City, UT 84117
Professional information
Christopher Pleiman - Holladay, UT
Work:
Medicine - Myriad (Myrexis) Pharmaceuticals, Inc
Director of Scientific Affairs and Translational/Experimental Myriad Pharmaceuticals, Inc
Director of Pharmacology Myriad Pharmaceuticals, Inc
Project Director of Pharmacology Inflammatory Disease Drug Discovery, Cadus Pharmaceutical Corp
Program Leader FcR1 Drug Discovery, Cadus Pharmaceutical Corp
Program Leader Cadus Pharmaceutical Corp
Scientist I, Drug Discovery Molecular Biology Group, Immunex Corporation
Associate Scientist
Director of Scientific Affairs and Translational/Experimental Myriad Pharmaceuticals, Inc
Director of Pharmacology Myriad Pharmaceuticals, Inc
Project Director of Pharmacology Inflammatory Disease Drug Discovery, Cadus Pharmaceutical Corp
Program Leader FcR1 Drug Discovery, Cadus Pharmaceutical Corp
Program Leader Cadus Pharmaceutical Corp
Scientist I, Drug Discovery Molecular Biology Group, Immunex Corporation
Associate Scientist
Education:
University of Washington
Ph.D. University of Washington
M.D. in research University of Colorado
Ph.D. in Department of Immunology
Ph.D. University of Washington
M.D. in research University of Colorado
Ph.D. in Department of Immunology
Director, Scientific Affairs At Myriad Pharmaceuticals
Location:
Greater Salt Lake City Area
Industry:
Pharmaceuticals
Methods Of Treating Cancer And Related Diseases
US Patent:
2011022, Sep 15, 2011
Filed:
Jan 11, 2011
Appl. No.:
13/004656
Inventors:
Christopher M. PLEIMAN - Salt Lake City UT, US
Gary G. MATHER - Salt Lake City UT, US
Gary G. MATHER - Salt Lake City UT, US
Assignee:
Myrexis, Inc. - Salt Lake City UT
International Classification:
A61K 31/517, A61P 35/00, A61P 35/04
US Classification:
5142664
Abstract:
Disclosed are orally bioavailable compounds effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, such as in cancer and related diseases.
Christopher Pleiman
Location:
Greater Salt Lake City Area
Industry:
Pharmaceuticals